For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Ngm Biopharmaceuticals, Inc.

USPTO Granted Patents = 73

% Expired Patents = 23.3

EPO Patents = 13

Forward Citations = 697

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Lei Ling (27 out of 29 patents)

Darrin Anthony Lindhout (27 out of 27 patents)

Hugo Matern (21 out of 21 patents)

4. Wenyan Shen (16 out of 47 patents)

5. Yan Wang (14 out of 14 patents)

6. Jian Luo (13 out of 32 patents)

7. Raj Haldankar (11 out of 11 patents)

8. Hui Tian (10 out of 18 patents)

9. Zhonghao Liu (10 out of 10 patents)

10. Betty Chan Li (10 out of 10 patents)

11. Kalyani Mondal (9 out of 9 patents)

12. Daniel David Kaplan (8 out of 8 patents)

13. Yu Chen (7 out of 12 patents)

14. Taruna Arora (7 out of 24 patents)

15. Jie Tang (5 out of 10 patents)

Core Competencies:

Metabolic Disorders

FGF19 Polypeptides

Glucagon Receptor

Beta Klotho

Binding Agents

Diabetes Treatment

Bile Acid Homeostasis

Triglyceride Levels

C3 Antibodies

LEAP2 Antibodies

Nonalcoholic Steatohepatitis

Wasting Syndrome

73 patents: Sort by Forward Citations

1. 12410251 - ILT-binding agents and methods of use thereof (2025-09-09),

2. 12378312 - Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof (2025-08-05),

3. 12240899 - LAIR-1-binding agents and methods of use thereof (2025-03-04),

4. 12187796 - ILT3-binding agents and methods of use thereof (2025-01-07),

5. 12180289 - Binding proteins and methods of use thereof (2024-12-31),

6. 12173060 - Compositions and methods of use for treating metabolic disorders (2024-12-24),

7. 11845802 - Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody (2023-12-19),

8. 11802155 - ILT-binding agents and methods of use thereof (2023-10-31),

9. 11767359 - C3-binding agents and methods of use thereof (2023-09-26),

10. 11760802 - ILT3-binding agents and methods of use thereof (2023-09-19),

11. 11732049 - Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor (2023-08-22),

12. 11667708 - Anti-human beta klotho antibody or binding fragment thereof and methods of their use (2023-06-06),

13. 11596676 - Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof (2023-03-07),

14. 11566067 - Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof (2023-01-31),

15. 11564972 - Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject (2023-01-31),

Company Overview

Ngm Biopharmaceuticals, Inc. is a biotechnology company based in South San Francisco, CA, specializing in the development of innovative therapies for metabolic disorders. The company focuses on advancing treatments that target key biological pathways, including FGF19 polypeptides and glucagon receptor interactions, to address conditions such as diabetes and dyslipidemia. Ngm is dedicated to improving bile acid homeostasis and regulating triglyceride levels, aiming to enhance patient outcomes in metabolic health.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

73 Patents

#20 in South San Francisco, CA

#1,187 in California

#5,042 in US

#10,273 in the World

South San Francisco, CA, United States of America

Ngm Biopharmaceuticals, Inc.

Forward Citations = 697

43 inventors:

Lei Ling (27 out of 29 patents)

Darrin Anthony Lindhout (27 out of 27 patents)

Hugo Matern (21 out of 21 patents)

4. Wenyan Shen (16 out of 47 patents)

5. Yan Wang (14 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ngm Biopharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/ngm-biopharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…